The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta (NCT01279369) | Clinical Trial Compass
TerminatedNot Applicable
The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta
Stopped: Quantitative assessment of fFN only able to be performed at one laboratory.
United States3 participantsStarted 2009-10
Plain-language summary
The purpose of this study is to determine if the presence of fetal fibronectin in the cervicovaginal secretions of pregnant patients with minor maternal trauma predicts impending preterm delivery due to abruptio placenta.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Singleton intrauterine pregnancy ≥20 weeks and ≤35 weeks gestational age
* Chief complaint of minor maternal trauma including motor vehicle accident, patient fall or assault with absence of maternal conditions outlined in exclusion criteria
Exclusion Criteria:
* Maternal shock
* Unstable vital signs
* Altered sensorium
* Head injury resulting in coma
* signs or symptoms of intraperitoneal bleeding
* Emergency laparotomy for fetal or maternal indications
* Bone fractures
* History of previous abruptio placenta
* Known or suspected placenta previa
* Rupture of membranes
* Multiple gestation
* Advanced cervical dilatation ≥3cm
* Non-reassuring fetal status requiring intervention
* Vaginal bleeding on presentation
* History of intercourse and/or digital vaginal exam and/or vaginal ultrasound ≤24 hours prior to presentation
* Illicit drug use